A comparison of two pancreatin microsphere preparations in cystic fibrosis.
OBJECTIVE
to compare the efficacy and tolerance of Creon and Pancrease in children and young adults with cystic fibrosis.


METHODS
a double blind, crossover study of two pH sensitive microsphere preparations of pancreatin (Creon, Pancrease), given in equivalent lipase dosage to 27 children with cystic fibrosis, was conducted.


RESULTS
at similar lipase activity no significant difference was found in the following: coefficient of fat absorption (CFA), coefficient of nitrogen absorption (CNA), weight gain, mean adequate daily intake for energy, and subjective symptoms. Three children who had a CFA less than 70% while receiving Pancrease all improved on Creon. No children had a CFA less than 70% while receiving Creon. A significant reduction in the number of capsules required daily to achieve similar control was possible when changing from Pancrease (mean 25/day) to Creon (mean 15/day). Seventy percent of patients preferred Creon and this was likely to be related to a perceived reduction in abdominal pain and stool frequency, and need for less capsules per day.


CONCLUSIONS
Creon and Pancrease are equally effective at doses providing equal lipase activity, however, the reduced number of capsules, fewer symptoms, and possible improvement of more severe steatorrhoea result in an increased patient preference for Creon.
Elliott
R B
RB
Department of Paediatrics, University of Auckland School of Medicine.
Escobar
L C
LC
Lees
H R
HR
Akroyd
R M
RM
Reilly
H C
HC
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004041:Dietary Fats / Q000032:analysis / Q000378:metabolism; D004311:Double-Blind Method; D002149:Energy Intake; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D008049:Lipase / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008863:Microspheres; D009584:Nitrogen / Q000032:analysis / Q000378:metabolism; D010184:Pancreatic Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D010194:Pancreatin / Q000008:administration & dosage / Q000627:therapeutic use*; D020799:Pancrelipase; D017060:Patient Satisfaction; D015430:Weight Gain
D004041:Dietary Fats; D010184:Pancreatic Extracts; D020799:Pancrelipase; D010194:Pancreatin; D008049:Lipase; D009584:Nitrogen